Could This Newly Approved Drug Improve Your Type 2 Diabetes?
If you have type 2 diabetes, your wellbeing could be improved by a newly approved drug from Sanofi and partner Zealand Pharma. The diabetes drug Lyxumia, which has just been given the green light by regulators in Europe, improves your wellness by helping you to achieve glycaemic control.
Lyxumia (lixisenatide), is a prandial GLP-1 receptor agonist that you take once a day. It is recommended for use in combination with oral glucose-lowering products and/or basal insulin, to achieve glycaemic control when you have type 2 diabetes. The European Commission has granted marketing authorisation in Europe for the drug, because of Sanofi’s GetGoal Phase III programme. This programme included 11 clinical trials involving more than 5,000 patients.
According to Pierre Chancel, head of global diabetes at the French drugmaker, because the manufacturer has the European thumbs-up, ‘we now have a simple new tool to help patients with type 2 diabetes further reduce HbA1c, with the benefit of weight loss and limited risk of hypoglycaemia’.
This gives Sanofi even more reason to celebrate, as just a few weeks ago the US Food and Drug Administration (FDA) gave their approval for Sanofi and Isis Pharmaceuticals’ Kynamro (mipomersen), which is a 200mg weekly subcutaneous injection for patients with homozygous familial hypercholesterolemia.
Comments are closed.